Dilated cardiomyopathy (DCM) is a deadly disease in which heterogeneous etiologies converge on heart failure, arrhythmias, and sudden death. Although alternative RNA splicing is associated with DCM, little is understood about specific molecular mediators of its pathogenicity. RBM20 is a cardiac muscle-specific splicing regulator of several important cardiomyocyte genes including those critical to excitation-contraction (EC) coupling. I have recently shown that DCM caused by genetic variants in RBM20 is particularly arrhythmogenic, with high rates of sudden death, suggesting that RBM20?s regulation of EC coupling may contribute to deadly arrhythmias in DCM. However, only one critical functional domain of RBM20 has been characterized, and while its overall expression has been associated with alternative splicing in DCM, the extent to which it directly controls splicing of key arrhythmia-associated genes in human heart failure is not known. Therefore, I hypothesize that regional genetic variation and decreased expression of RBM20 lead to aberrant splicing of calcium handling genes, disrupting EC coupling in human DCM. To address this hypothesis, I will undertake three experimental aims: First, I will determine sequence- function relationships of variants in two regions of RBM20 highly predicted by my preliminary data to represent functional domains. I will accomplish this using high throughput saturation gene editing of these regions in induced pluripotent stem cell-derived cardiomyocytes (iPSC-CM) and test the functionality of resultant genotypes by assessment of RBM20?s splicing activity. Second, to identify all RBM20-associated splicing targets relevant to EC coupling, I will analyze global short read RNA-sequencing (RNA-seq) data from human cardiac tissue with low vs. high RBM20 expression. I will go on to directly manipulate RBM20 expression in iPSC-CMs and use long read RNA-seq to characterize full length isoforms of those targets under the condition of RBM20 knockdown. Lastly, I will define the mechanism by which the aberrant splicing of two known arrhythmia-associated RBM20 splicing targets disrupts EC coupling. To do this, I will use targeted gene editing to correct their aberrant splice isoforms in RBM20+/- and RBM20-/- iPSC-CMs and measure the effect of this manipulation on EC coupling-related phenotypes that I have previously established in these cell lines. These experiments will provide a broad basis for my future studies of global sequence-function relationships across the length of the RBM20 transcript, as well as my future investigation of measurement and modulation of RBM20 function to improve prognosis in DCM patients at high risk of sudden death. At the same time, this project will develop my skills in computational biology, gene editing, and single cell electrophysiology critical to this future investigation. Taken together, the proposed work will produce an innovative, multimodality examination of the role of RBM20 in arrhythmia and sudden death associated with DCM.
Dilated cardiomyopathy (DCM) is a deadly disease that can lead to arrhythmias and sudden death. Many underlying causes of DCM lead to common end-stage disease characteristics, yet a handful of therapies are used to treat all underlying causes, rather than tailoring treatment to specific patients? disease. Here, I will illuminate the potential for more individualized therapies by investigating how unique changes in a specific gene and its molecular products control deadly arrhythmias, thus identifying novel potential diagnostic and therapeutic targets to prevent them.
